tbuckley/cabot-search huggingface dataset:
Teratological Research Using In Vitro Systems. I. Mammalian Whole Embryo Culture
Authors: Thomas J. Flynn
Journal: Environmental Health Perspectives (1987)

Approximately 390 literature references (through spring 1986) were reviewed for mammalian whole embryo culture procedures, with particular attention to the development of those cultures as systems for teratogenicity testing. The existing procedures could be conveniently divided into three groups, which are defined by the periods of embryogenesis that they embrace: preimplantation, peri-implantation, and post-implantation culture systems. The literature on peri-implantation embryo culture was sparse, and it did not appear that this procedure is being actively developed as a teratogen screening test. The extensive literature on both preimplantation and postimplantation embryo culture suggested considerable use of these two methods in evaluating embryotoxicants. The following discussion was compiled from information gleaned from all references. However, in the interest of brevity, only representative articles are specifically cited. Because the background and methodology for each system are distinct, each system will be discussed separately.
A Text-Book of Bacteriology.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POLAND
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Symposium on Silicosis
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thiazide-induced hypokalemia with associated major ventricular arrhythmias. Report of a case and comment on therapeutic use of bretylium
Authors: P. D. Redleaf
Journal: JAMA (1968)

A 48-year-old woman survived multiple episodes of ventricular tachycardia, flutter, and fibrillation which were associated with a profound thiazide-induced hypokalemia. The significant features of the case are (1) the dosage of hydrochlorothiazide was quite modest, (2) the patient had no known underlying heart disease and was not receiving digitalis, and (3) the arrhythmias were remarkably refractory to the usual therapeutic measures. When recurring ventricular tachyarrhythmias could not be controlled with quinidine sulfate, procainamide hydrochloride diphenylhydantoin sodium, and lidocaine hydrochloride, treatment with bretylium tosylate was instituted. No further episodes occurred thereafter, and it was possible to discontinue this agent without ventricular automatism after potassium repletion had been accomplished. Bretylium appears to be a new and effective agent for the control of major ventricular arrhythmias.
Disentangling Kaposi's sarcoma.
Journal: BMJ (1978)

set out hierarchies of risk and benefit and state that "in determining whether children are capable of assenting the Board shall take into account the ages and maturity of the children involved."Nevertheless, while the more flexible interpretation of the law may prove to be correct, some authorities still take a conservative line.A mature individual is free to take an altruistic decision to risk personal harm in the cause of science: taking such a decision by a parent on behalf of his child remains nuestionable.The arguments are finely balanced: possibly they can be resolved only by legislation.Furthermore, as Dr Skegg himself emphasised, research that is legally unobjectionable may nevertheless be unethical.For this reason hospital ethical committees have a most important function in protecting the individual against the overzealous investigator.Whether or not these committees should attempt to assess the scientific merits of research proposed to them is debatable; but in the case of children their primary duty must be to ensure that the research is neither harmful nor unkind and that the risk-benefit ratio is acceptable.5At a time when there is so much public questioning of medical traditions, and especially of medical authoritarianism, research workers need to be especially careful not to offend these heightened susceptibilities.
Instructions for Authors
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does Delayed Childbearing Increase Risk?
Authors: Frederick D. Bartholomew
Journal: JAMA (1993)

<h3>To the Editor.</h3> —The study by Cnattingius et al<sup>1</sup>attempted to control many variables, leaving advanced maternal age as an independent risk factor for increasing perinatal morbidity and mortality. However, we have several concerns about the methods used. Most significantly, in an article attempting to show an association between advanced maternal age and increased perinatal morbidity and mortality, we find it interesting that no specific mention is made of the neonatal outcome, such as chromosomal aneuploidy. What percentage of these infants had structural anomalies? Indeed, there is no mention of the specific causes of adverse neonatal outcomes. It is imperative in a study of this nature to control for fetal as well as maternal variables. Additionally, we would like more information on the nature of prenatal care in Sweden. What is routine to the investigators may not be routine in the United States. Specifically, what percentage of the population
<i>Erratum:</i> Vol. 66, No. 27
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In "Racial and Geographic Differences in Breastfeeding-United States, 2011-2015," on page 723, in the first paragraph, the fifth sentence should have read, "Among the 34 states (including the District of Columbia [DC]) with sufficient sample size (≥50 per group), initiation rates were significantly (p<0.05)lower among black infants than white infants in 22 states; in 14 of these states (primarily in the South and Midwest), the difference was at least 15 percentage points."On page 727, under "What is added by this report?" the second sentence should read, "Breastfeeding initiation rates were significantly lower among black infants in 22 states; in 14 of these states, the difference was at least 15 percentage points."
BASE BALANCE IN THE BODY
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endometrial Sclerosis
Authors: Charles E. Gibbs
Journal: JAMA (1964)

FOR THE past several years the literature has contained an increasing number of reports of cases of fibroinflammatory changes in the endometrium which resulted in various menstrual and pregnancy problems. The authors have applied a variety of terms to this condition. Generally, the European and Asian investigators have used the terms "traumatic amenorrhea"<sup>1</sup>and "intra-uterine adhesions."<sup>2-4</sup>American authors have called essentially the same condition "adhesive endometritis" and "endometrial sclerosis."<sup>5</sup>Asherman of Israel<sup>1,2</sup>was the first to discuss the condition thoroughly and draw attention to many of the salient features. Because of his reports, it has also been called Asherman's syndrome.<sup>6</sup> The condition may be defined as a state in which the uterine walls become adherent to each other, in part or in whole, resulting in a diminished intrauterine cavity, and characterized clinically by menstrual abnormalities, infertility, and/or habitual abortion. We have had some experience with
Abrupt discontinuation of clonidine therapy
Authors: C. V. Ram
Journal: JAMA (1979)

Clonidine therapy was discontinued abruptly in seven patients. Blood pressure was recorded every hour or two hours throughout the study. Clonidine therapy was reinstituted 48 hours after its discontinuation in all except two patients, in whom it was reinstituted at 36 hours. During the withdrawal phase, blood pressure tended to return rapidly to nontreatment levels, but there was no "overshoot" in blood pressure. Apprehension, insomnia, palpitations, and sweating were experienced by two patients. These symptoms were relieved promptly by reinstituting clonidine therapy. In this prospective study, no blood pressure overshoot was noted with abrupt discontinuation of clonidine. (<i>JAMA</i>242:2104-2105, 1979)
Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Authors: Omid Hamid, Todd Michael Bauer, Alexander I. Spira, Anthony J. Olszanski, Sandip Pravin Patel, Jeffrey S. Wasser, David C. Smith, Ani Sarkis Balmanoukian, Charu Aggarwal, Emmett V. Schmidt, Yufan Zhao, Hema Gowda, Tara C. Gangadhar
Journal: Journal of Clinical Oncology (2017)

6010 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that induces immune tolerance by T-cell suppression. IDO1 overexpression has been associated with poor survival in SCCHN. Epacadostat (E) is a potent, selective oral IDO1 inhibitor. ECHO-202/KEYNOTE-037 is an open-label, phase I/II (P1/2) study evaluating E plus PD-1 inhibitor pembrolizumab (P) in multiple tumor types. We report preliminary P1/2 efficacy, safety, and tolerability findings in the SCCHN cohort as of a 29OCT2016 data cutoff. Methods: Eligible adult patients (pts) had metastatic SCCHN and received ≥1 prior chemotherapy regimen that included a platinum agent. Prior checkpoint inhibitor therapy (tx) was not permitted, and pts with carcinoma of the nasopharynx or salivary gland were excluded. In P1 dose escalation (3+3+3), pts received E (25, 50, 100, or 300 mg PO BID) + P (2 mg/kg or 200 mg IV Q3W); MTD was not exceeded. E (100 mg BID) + P (200 mg Q3W) dosing was selected for P2 cohort expansion. Response was assessed in RECIST 1.1 evaluable pts. Results: A total of38 pts (P1, n = 2; P2, n = 36) were evaluated. Median age was 63 years, 87% of pts were men, 95% were white, and 66% received prior cetuximab. Of 36 efficacy-evaluable pts, 81% (n = 29) received 1–2 prior lines of tx and 19% (n = 7) received ≥3 prior lines of tx. ORR (CR+PR) and DCR (CR+PR+SD) for pts with 1–2 prior tx were 34% (2 CR, 8 PR) and 62% (8 SD), respectively; for pts with ≥3 prior tx, ORR and DCR were 14% (1 PR) and 43% (2 SD). Response was observed regardless of HPV status. At data cutoff, 9/11 responses were ongoing (range, 1+ to 563+ days). PFS and biomarker analyses are ongoing. The most common TRAEs in all 38 pts were fatigue (24%), nausea (11%), and decreased weight (11%). Grade ≥3 TRAEs occurred in 11% of pts; only increased amylase and lipase (both asymptomatic) were grade ≥3 TRAEs that occurred in &gt; 1 pt. TRAEs led to discontinuation in 1 pt (increased amylase and lipase). Conclusions: In pts with advanced SCCHN, E + P was generally well tolerated and associated with encouraging response rates, particularly in pts with 1–2 prior lines of tx. A phase III SCCHN study is planned. Clinical trial information: NCT02178722.
CLAUDE BERNARD
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DIRTY RESTAURANT KITCHEN.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
METB-15. REGULATION OF BIOENERGETICS THROUGH DUAL INHIBITION OF ALDEHYDE DEHYDROGENASE AND MITOCHONDRIAL COMPLEX I SUPPRESSES GLIOBLASTOMA TUMORSPHERES
Authors: Junseong Park, Jin-Kyong Shim, Joon Hee Kang, Eui Hyun Kim, Jong Hee Chang, Soo-Youl Kim, Seok-Gu Kang
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM), the most common primary brain tumor, continues to be associated with poor prognosis despite the best treatment modalities currently available. Targeted approaches for treating GBM attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles. Bioenergetics deprivation has emerged as an effective therapeutic approach for various tumors. We have previously found that cancer cells preferentially utilize cytosolic NADH supplied by aldehyde dehydrogenase (ALDH) for ATP production through oxidative phosphorylation (OxPhos). This study is aimed to examine therapeutic responses and underlying mechanisms of dual inhibition of ALDH and OxPhos against GBM. For inhibition of ALDH and OxPhos, the corresponding inhibitors, gossypol and phenformin were used. Biological functions, including ATP levels, stemness, invasiveness, and viability, were evaluated in GBM tumorspheres (TSs). Gene expression profiles were analyzed using microarray data. In vivo anticancer efficacy was examined in a mouse orthotopic xenograft model. Combined treatment of GBM TSs with gossypol and phenformin significantly reduced ATP levels, stemness, invasiveness, and cell viability. Consistently, this therapy substantially decreased expression of genes associated with stemness, mesenchymal transition, and invasion in GBM TSs. Supplementation of ATP using malate reversed these effects, whereas knockdown of ALDH1L1 mimicked them, suggesting that disruption of ALDH-mediated ATP production is a key mechanism of this therapeutic combination. In vivoefficacy confirmed remarkable therapeutic responses to combined treatment with gossypol and phenformin. In this study, we showed that combined treatment with gossypol and phenformin induces dual inhibition of bioenergetics by targeting ALDH and OxPhos, causing ATP depletion in GBM TSs. This regimen subsequently attenuated stemness, mesenchymal transition, and invasion, which are prominent features of GBM TSs, ultimately leading to a decrease in cell viability. Our findings suggest that dual inhibition of tumor bioenergetics is a novel and effective strategy for the treatment of GBM.
Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T Cell Expansion.
Authors: Dorit Fabricius, Angelika Vollmer, Sue Blackwell, Julia Maier, Kai Sontheimer, Thamara Beyer, Birgit Mandel, Oleg Lunov, Kyrylo Tron, G. Ulrich Nienhaus, Thomas Simmet, Klaus-Michael Debatin, George J Weiner, Bernd Jahrsdoerfer
Journal: Blood (2009)
A LETTER FROM MOSCOW
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
β-Thalassemia
Authors: Deborah Rund, Eliezer Rachmilewitz
Journal: New England Journal of Medicine (2005)

β-Thalassemia, which is caused by a decrease in the production of β-globin chains, affects multiple organs and is associated with considerable morbidity and mortality. Lifelong care is required, and the costs of proper treatment are substantial. This review discusses current approaches to the management of β-thalassemia.